Abstract
Introduction

Oxygen-sensing mechanisms enable the cell to adapt to low oxygen environments and are also critical for normal development and apoptosis. Disruptions of oxygen-sensing pathways can lead to the development of certain forms of cancer [1-15]. Oxygen sensing is mediated partly via the EglN hydroxylases (EglN1/ EglN2/EglN3) that are dependent upon molecular oxygen, iron (II)
and ␣-ketoglutarate to perform proline hydroxylation on their target [16] [17] [18] [19] [20] . Therefore these enzymes are considered oxygen and also metabolic sensors. The availability of molecular oxygen is absolutely required for the hydroxylation reaction, because it donates the oxygen atom to the hydroxyl group [21] . 
But equally important for the hydroxylation reaction is the electron donor ␣-ketoglutarate, a metabolite from the Krebs cycle. Since EglN is dependent upon metabolites that take part in the Krebs cycle, they are directly tied into the cellular metabolic network (Fig. 1). The first identified substrate for the EglN prolyl hydroxylases is the transcription factor hypoxia inducible factor ␣ (HIF-␣) [16, 17]. The identification of HIF-␣ as a direct hydroxylation substrate provided the first and direct link between tumour suppressor function and oxygen sensing. The tumour suppressor von Hippel
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://www3.interscience.wiley.com/authorresources/onlineopen.html Lindau (VHL) acts as an ubiquitin ligase by targeting hydroxylated HIF-␣ for degradation when oxygen is available, as where under low oxygen environments, HIF-␣ escapes hydroxylation and subsequently escapes VHL recognition [3-5, 16, 22-27]. The escape from VHL recognition allows HIF-␣ to accumulate and to transactivate its target genes that are important for adaptation to low oxygen environment including energy metabolism and angiogenesis [28-30]. Both HIF-dependent and HIF-independent VHL functions contribute to VHL-defective tumorgenesis [31-34]. The VHL disease is caused by inactivating germline mutations of the VHL gene and predisposes to a variety of tumours including haemangioblastoma of the retina and nervous system, clear cell renal carcinomas (RCC; the most common form of kidney cancer) and phaeochro
Lessons from a rare disease
Phaeochromocytomas are rare, with only five to eight cases diagnosed per million people a year [39] . They are neoplasias of neural crest origin arising from the adrenal medulla. Phaeochromocytomas can also develop in extra-adrenal sympathetic ganglia 10% of the time. Extra-adrenal phaeochromocytomas are sometimes referred to as paragangliomas [40] . In short, these tumours are sympathetic nervous system tumours. [40] . Given the evidence that NF1 promotes sympathetic neuronal survival and further that these neoplasias originate from the sympathetic nervous system, a closer look into the sympathetic neuronal development reveals important clues to the genesis of these tumours [9] .
Since the discovery by Rita Levi-Montalcini and Viktor Hamburger of the neurotrophic factor NGF, our understanding of developmental apoptosis in the sympathetic nervous system has greatly increased [42] . During neuronal development, NGF is required for survival but is also limiting. Neurons that successfully compete for NGF during development survive whereas unsuccessful neurons die. Competition for NGF is an important developmental process for matching the size of a neuronal population, especially in the peripheral nervous system [43] . As much as 50% of neurons produced during embryogenesis die by apoptosis during neuronal development. Abnormal NGF signalling has been linked to paediatric nervous system tumours such as neuroblastoma [44, 45] and diseaseassociated mutations such as NF1 have been shown to enhance signalling by NGF receptors and promote neuronal survival in the absence of NGF [41] . In the last decades it became evident that JNK/c-Jun signalling is required for apoptosis when NGF is limiting in the developing nervous system [46] [47] [48] [49] [50] . Interestingly, the prolyl hydroxylase EglN3 has recently been implicated in this pathway. EglN3 is induced in sympathetic neurons deprived of NGF and further has pro-apoptotic activity when overexpressed [51] 
. Given that EglN3 is known to hydroxylate HIF-␣ and has been implicated in developmental apoptosis in sympathetic neurons, the following questions arise: (i ) Does EglN3-mediated apoptosis depend upon its hydroxylation activity? (ii ) Does it depend upon HIF hydroxylation or does it involve hydroxylation of unknown substrates? (iii ) Is failure of EglN3-mediated apoptosis implicated in the genesis of phaeochromocytomas and other tumours arising from the neural crest origin?
Specificity of function within the EglN prolyl hydroxylases
The ability of EglN3 to induce neuronal apoptosis appears to be unique among the EglN family members [9] . Induction of apoptosis is dependent upon EglN3 hydroxylation activity, because catalytic impaired EglN3 fails to induce apoptosis [9, 52] . Importantly, [53] [54] [55] [56] [57] . However, EglN1 appears to be the primary HIF prolyl hydroxylase under normal conditions [58] . Consistent with this, mice lacking EglN2 or EglN3 are viable and grossly normal whereas mice lacking EglN1 are not viable [59] . Conditional inactivation of EglN1 in mice leads to polycythemia due to HIF-␣ stabilization and increased transcription of HIF target genes including erythropoietin [60, 61] [51] . Overexpression of EglN3 is sufficient to promote cell death in NGF-maintained sympathetic neurons [51, 73] . Cell death is caspase dependent and accompanied by an increase of cytochrome c in cytosolic and mitochrondria-enriched subcellular fractions [74] . [76, 77] [52] . [79, 80] . The recent study, which identified KIF1B␤ as an EglN3 downstream target showed how KIF1B␤ is both necessary and sufficient for neuronal apoptosis when NGF becomes limiting, but it remained unclear how EglN3 regulates KIF1B␤ [64] . Interestingly, KIF1B␤ maps on to the chromosomal region 1p36.2, a region of the genome that is frequently deleted in neural crest-derived tumours including neuroblastomas [81] . The existence of one or more human tumour suppressor genes on chromosome 1p has been suspected for decades [82] [83] [84] [64, [85] [86] [87] [88] . Perhaps KIF1B␤ haploinsufficiency is adequate for tumorgenesis in some contexts. Also, the existence of multiple neuroblastoma and phaeochromocytoma suppressor genes on 1p has been suggested [89, 90] [94, 95] . Loss of function mutation in IDH1 results in a decrease of intracellular ␣-ketoglutarate. Subsequently EglN prolyl hydroxylases are inhibited in their hydroxylase activity with the consequences of HIF-␣ stabilization [14] . Presumably EglN3-mediated apoptosis might be impaired in these settings as well, but this has not been investigated yet. Further, these studies follow the discoveries that germline mutation in SDH are linked to phaeochromocytoma and that FH mutation lead to leiomyosarcoma and renal cell carcinoma, both of which affect also the EglN prolyl hydroxylase activity [9, 10, 71] . This is because loss of function mutation in SDH and [9, 10, 71, 96] . [97, 98] 
EglN3-induced apoptosis is not diminished in the presence of stable HIF1␣ or HIF2␣ variants that cannot be hydroxylated on their prolines [9]. This suggests that hydroxylation targets of EglN3 other than HIF-␣ are crucial for apoptosis function. EglN2 and EglN3 are induced by hypoxia and dampen the HIF-␣ response under chronic hypoxia
Understanding the mechanistic basis of EglN3 killing
EglN3-mediated apoptosis is hydroxylation dependent, but independent of HIF-␣ hydroxylation [9]. An important challenge is to identify the link between this enzyme and apoptosis, which presumably involves hydroxylation of a protein other than HIF-␣. Early studies indicated that EglN3 mRNA and protein expression (at that time referred as SM-20) increases shortly after removal of NGF in primary sympathetic neurons and peaks between 10 and 15 hrs at a time when cells undergo apoptosis
The mechanism underlying EglN3-induced cytochrome c is not known although it appears to involve an increase in cytochrome c mRNA. Other studies have identified EglN3 as a growth factor inducible gene in vascular smooth muscle cells [75] and later proposed, that it might function in growth arrest, differentiation and cell death during muscle differentiation
. Expression of EglN3 was also reported in fibroblasts upon activation of a temperature-sensitive form of p53 [78]. However, EglN3-induced apoptosis appears not to be impaired in cells lacking p53 or expressing a dominant negative p53 protein, indicating that p53 might not function downstream of EglN3 to induce apoptosis [9]. In addition, a recent study indicated that EglN3's ability to induce apoptosis correlates with the formation of aggresome-like structures
Recently, an unbiased genome-wide approach has been undertaken to understand how EglN3 causes neuronal cell death. A short interference RNA library was used to identify genes that suppress EglN3-induced apoptosis [64]. This led to the identification of the kinesin KIF1B␤ as a downstream effector of EglN3. KIF1B, a member the kinesin 3 family, consists of two major splice variants ␣ and ␤. KIF1B␣ and KIF1B␤ are motor proteins implicated in anterograde transport of mitochondria and synaptic vesicle precursors, respectively
FH increases the accumulation of succinate and fumarate respectively. The excess of these metabolites inhibits the proline hydroxylases with the consequences in either accumulation of oncogenic HIF-␣ and/or blunting EglN3-mediated apoptosis
Future directions
The recently identified mutations in the metabolic/mitochondrial enzymes (FH, SDHB/C/D, IDH1/2) provide convincing evidence that alteration in cellular metabolism contributes to the pathogenesis of cancer. Hence, 43 years later we are beginning to learn the depth of Otto Warburg's foresight that (in his words) 'cancer cells should be interpreted as a mitochondrial dysfunction' and that 'the prime cause of cancer is the replacement of the respiration of oxygen in normal body cells by a fermentation of sugar'
